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The report describes the feasibility of the addition of multiple viable HLA-mismatched unrelated cord blood units, to a low cell
number matched unrelated cord, to assist clinical engraftment. An ablative stem cell transplant was performed in an adult with
relapsed acute lymphoblastic leukaemia (ALL), using a single HLA-matched cord blood unit (mononuclear cell dose 0.8 × 107),
supported by six mismatched cord blood units (one unit per 10kg recipient weight). No adverse reaction occurred following the
infusion of mismatched units and engraftment of the suboptimal-dose matched unit occurred rapidly, with no molecular evidence
of engraftment of mismatched cords. Early molecular remission of ALL was demonstrated using a novel PCR for a mitochondrial
DNA mutation in the leukaemic clone. The cell dose of the matched cord was well below that recommended to engraft a 70kg
recipient. We suggest that a factor or factors in the mismatched cords enhanced/supported engraftment of the matched cord.
1.Introduction
The value of cord blood (CB) as a source of stem cells
for transplantation in adults has been enhanced by the
key observations that engraftment and outcome can be
facilitated by the use of two partially matched cords [1, 2].
This approach has been used to increase overall stem cell
number and appears to create a pattern of engraftment,
and clinical outcome similar to that of matched unrelated
bone marrow transplant of adult to adult [3]. CD 34+ cell
dose has been considered critical for safe engraftment and
the threshold level recommended is > 1.7 × 105 kg [4], or
a total doses of nucleated cell (TNC) > 3.7 × 107 have
been considered necessary [5], hence the use of two cords,
to overcome this dose problem when transplanting adults.
However, it is usual that only one of the infused cords
engrafts which raises the question of additional factors in
the nonengrafting cord that might facilitate the engraftment
process.
Evidence has now emerged in a NOD/SCID mouse
model, that use of two cords will enhance engraftment even
when compared with single units containing the same cell
numbers as the combined cords [6]. The authors of these
studies conclude that the results indicate that engraftment
may be enhanced by addition of a second unrelated CB
and may be attributed to cell dose increase or due to as yet2 Stem Cells International
unknown factors providing a graft-facilitating eﬀect, since
engraftment often occurs in this setting with only one of the
pair of cords successfully engrafting.
Additionally, observations of experimental transplants
in humans using multiple totally mismatched cords, which
demonstrate some engraftment [7, 8], also provide intrigu-
ing evidence to suggest that novel approaches to enhance
cord engraftment are warranted, in otherwise fatal clinical
situations.
In this preliminary report we describe the use of a very
low dose, matched cord unit (0.8 × 107/kg mononuclear
cord cells), utilised successfully to engraft an adult patient
supported by the use of multiple (six) mismatched viable
cords that did not themselves engraft.
2. Case History
In 2001 a 31-year-old white male (wt 70kg) presented
with acute lymphoblastic leukaemia in November 2000.
Peripheral WBC was 82 × 109/L. The tumour was CD10+,
CD13+, CD19+, CD20+, CD33+, CD34+, HLADR+, and
TDT+. Standard cytogenetics failed, but cells were BCR/ABL
negative by PCR. He was treated with an aggressive mul-
tiagent chemotherapy schedule (Northern Region Haema-
tology Group NEALLVI) for a six-month period. An
attempt at the end of therapy to harvest peripheral blood
stem cells failed. There was no sibling donor or adult
matched unrelated haemopoetic stem cell (HSC) donor
available. Six months after completing the protocol he
relapsed. Reinduction with further aggressive chemotherapy
(FLAG-ﬂudarabine, cytosine arabinoside and GCSF) was
completed causing sustained and irrecoverable marrow
hypoplasia with persistence of small numbers of leukaemia
blasts.
With no adult HSC donor available we identiﬁed a fully
HLA-matchedmalecordbloodunit(totalnucleatedcelldose
1.4×107/kg,mononuclearcelldose0.8×107/kg),CD34dose
unavailable. This matched unit was blood group O, and the
recipient was blood group A. This single unit was (in 2002
the date of transplant) considered insuﬃcient to guarantee
engraftment in a 70kg recipient. After detailed discussions
with patient and relatives, and considering preliminary data
from Gryn et al. [7], six additional totally HLA-mismatched,
blood group matched, female cord blood units were selected
from the Newcastle Cord Bank to increase the stem cell
component.
Preconditioning consisted of Rituximab (anti-CD20
antibody) for four doses (325mg/sq·m per dose), over 8
days. Marrow blast content was unchanged directly after
this treatment. Additional preconditioning consisted of
intravenous Melphalan 120mg/m2 plus TBI of 1200cGy in
six fractions over three days. Intrathecal methotrexate was
also utilised. The HLA-matched cord unit was given prior
to the nonmatched cord units to facilitate predominant
engraftment with the matched element. The remaining cord
units were all given over a one-hour period four days
later. Nucleated cell content of these units is shown in
Table 1.
2.1. Engraftment. Details of the single matched cord engraft-
mentaretabulatedinTable 2.Whitebloodcellreconstitution
showed a level of 1.3 × 109/L on day +28 and a staggering
granulocyte count of 7.45 × 109/L on day +32 which
reduced subsequently as GM CSF (started on day +7) was
discontinued. All white cells were from the matched cord
unit. Platelet engraftment, as anticipated, was slow and did
not reach a level of 30 × 109/L unsupported until day 120
(Table 2).
Molecular markers of the leukaemic clone
(immunoglobulin heavy chain markers (IgH/VH1/VH2)
and T cell gamma gene rearrangement (courtesy of Dr. L.
Foroni, Royal Free Hospital, London) disappeared in clinical
remission after chemotherapy, returning on subsequent
relapse. These markers were no longer identiﬁable in the day
100 sample, post cord blood transplant.
Genotype tracking of all transfused mismatched cord
blood units used was performed by VNTR analysis using
three microsatellite loci (TNFa and TNFd (6p21.3) and
the CTLA4 locus (2q33)). All transfused units had unique
genotypes using these markers (Table 1). On Day +5 trace
of the patient’s genotype was detectable and subsequently
became undetectable. The HLA-matched cord unit genotype
was detected from day +7 with only weak signals from
any of the nonmatched cord genotype between day’s 5–7
after which they disappeared. (sensitivity of detection of this
analysis is 2%–5 %).
In a separate study of mitochondrial mutations in
haematological malignancy, the leukaemic cells from this
patient were shown to have a somatic mitochondrial DNA
mutation in the cytochrome b gene (He et al. [9]). A sensitive
speciﬁc PCR assay for detection of the mutation showed
the mutation to be present at diagnosis and in relapse cells.
After cord unit transplant there was no evidence of this
mutation in the bone marrow, either at day +28, +100, or
+140 indicating molecularremission atthatstage(sensitivity
of detection <0.1% using a quantitative SYBR Green real-
time PCR assay, see He et al., [9] for details). The day 100
bonemarrowwaspopulatedonlybythematchedcord(FISH
100% chimaerism).
3. Discussion
Cord blood transplant can be safely considered in adults
using a single suitable cord unit, and results are suﬃciently
good to recommend the approach when there is no suitable
adult donor [10]. The issue relates to the cell dose and
speed and safety of engraftment, and anything that can
improve this consistently has clear interest. Recent results
have conﬁrmed that it is a major problem to transplant with
< 2 × 107/Kg nucleated cells [11, 12] though Takahashi et
al. did see delayed engraftment in seven transplants with
1–2 ×107/Kg.
Clearly, there appears to be much merit in double cord
transplant with partial matching of the units [1–3], and
the striking observation of Gryn et al. [7]c o n ﬁ r m e di na
later report by Lister et al. [8] that sustained engraftment
can occur with completely mismatched cord units, led toStem Cells International 3
Table 1: Details of transplanted cord units. Cellular characteristics and HlA types of the cord units used in the transplant are given. No
attempt was made to have matching tissue types in the unmatched cords. The matched cord diﬀered from the patient in blood group Patient
A+ matched cord O+. Tissue type of matched cord was identical at Class 1 DR, and DP were fully matched but there was a DQ mismatch.
All cord donations were female and CMV antibody negative Genotypes are the allele ID’s for the markers used at the CTLA4 and TNFA loci
(refs). The matched cord cell dose was substantially less than the recommended dose for engrafting an adult (0.8 ×10
7/kg) but engraftment
of granulocytes was swift and uncomplicated. NK-not known.
Sample description
Blood group and
Hla types of
transfused cord
units
Total NUC
cell count
× 107
Nucleated
cell count
107/kg
MNC ×107
Total
CD34 ×108
Total
CTLA4
microsatellite
genotype
TNF
microsatellite
genotype
Patient leukaemia — — — — — 27, 28 a2,7; d3,4
Matched cord
O Pos and A29,
A68, B44,
B1402/04/06
Cw08, Cw1601,
DRB1, DQB1,
DPB1
102 1.46 56.2 (0.8
×107/kg) - NK 16, 19 a2,7; d4,4
Nonmatch cord 1
A Pos and A2, A11,
B8, B35, Cw7,
Cw4/18, DR1
66.6 0.95 - NK 0.36 8, 16 a6,10; d3,3
Nonmatch cord 2
A Pos and A1, A11,
B18, B38, Cw12,
Cw7, DR13, DR15
132.8 1.89 - NK 0.292 8, 8 a2,2; d1,4
Nonmatch cord 3
A Pos and A1, A26,
B8, B49, Cw7,
DR1, DR17
159.8 2.28 - NK 0.639 8, 22 a2,5; d1,3
Nonmatch cord 4
AP o sa n dA 1 ,A 2 ,
B8, B27, Cw2,
Cw7, DR17
80.2 1.15 - NK 0.217 8, 19 a2,2; d1,4
Nonmatch cord 5
A Pos and A2, B44,
B60, Cw5, Cw10,
DR13, DR15
64.6 0.92 - NK 0.058 19, 22 a4,11; d3,3
Nonmatch cord 6
AP o sa n dA 2 ,A 3 ,
B7, B60, Cw7,
Cw10, DR4, DR17
91.4 1.31 - NK 0.165 8, 8 a2,11; d3,4
Patient blood +21
days — — — — 16, 19 a2,7; d4,4
Table 2: Pattern of haematological engraftment. Cell counts and tracking data for the post transplant period. A relative monocytosis and
eosinophillia has persisted throughout the engraftment period. Marrow at day 28, 100 and 140 demonstrates molecular remission using
MRD markers.
(×109/l) Day
1
Day
15
Day
21 Day 28 Day
32
Day
36
Day
40 Day 50 Day
75 Day 100 Day 140
Total WCC 0.00 0.4 0.6 2.3 8.8 6.8 5.0 10.3 5.6 4.6 11.1
Neutrophils 0.03 0.04 0.33 1.3 7.45 3.5 2.46 7.37 2.53 1.98 5.97
Lymphocytes 0.01 0.29 0.15 0.26 0.19 0.84 0.8 0.29 0 1.0 1.03
Monocytes 0.00 0.02 0.16 0.65 1.02 1.43 1.14 1.63 0.91 0.95 2.60
Eosinophils 0.00 0.00 0.00 0.12 0.02 1.1 0.56 0.8 1.78 0.3 1.4
Basophils 0.00 0.00 0.00 0.01 0.15 0.01 0.08 0.14 0.14 0.13 0.05
Haemoglobin 8.7 11.1 10.8 10.4 11.1 10.6 10.4 10.0 11.6 (unsupptd)
Platelets 22 24 18 42 14 8 14 36 58 (unsupptd)
Blood gp A-
mitochondrial
DNA mutation
(marrow) +ve
IgH (V2) +ve
Mitochondrial
DNA mutation
(marrow) −ve
Blood Group O
+ ve conﬁrmed
Mitochondrial
DNA mutation
(marrow)
−ve IgH (V2)
−ve
Mitochondrial
DNA mutation
(marrow) −ve4 Stem Cells International
the approach described here, that of mismatched cord units
supporting a small matched cord unit. Since this procedure
occurred in 2002 before double cord transplants with partial
matching were established, we were uncertain as to the
number of additional completely mismatched cords that
would be required. The choice of six additional cords related
tothesmallamountofdataonusingcompletelymismatched
units alone (7), so this number was adopted arbitrarily to
ensurethatahightotaldosewasdelivered.Thechoiceofcord
HLA type between additional cords was not a consideration;
themainfeaturesweretheywerethesamebloodgroupasthe
recipient; all female donors aid tracking and CMV negative.
Clinically this procedure was an uncomplicated stem
cell transplant with no immediate or delayed reaction to
the mismatched cord units. Immunosuppression was with
cyclosporine A alone, which was discontinued on day +30,
and no acute graft versus host disease occurred.
There was rapid engraftment of the granulocyte series
(Table 2) and only transitory evidence of the DNA from the
other six cord units early in the posttransplant period. In
double cord transplants the pattern of engraftment observed
is that usually there is the emergence of an individual single
cord as the dominant element, but there can be mixed
chimeras. In double cord transplants, however, there is
usually at least partial matching with the patient and the
other cord [1].
The speed and extent of myeloid engraftment of the low-
dose HLA-matched CB unit in this patient, with neutrophils
of 7.45 × 109/l on day 32, raises the question of whether
the other cord units supported engraftment as suggested
in the SCID model [6]. The use of seven cords in total is
related to the observation of Gryn et al. [6]o fu s i n go n ec o r d
unit per 10 Kg body weight of the recipient. Applying this
approach in our patient was uncomplicated and provides a
modelforfurtherexperimentalapplications.Thesubsequent
course was punctuated by an encephalopathic illness caused
by HHV6 infection, which was satisfactorily treated using
Foscarnet over several weeks.
The novel mitochondrial DNA mutation which was
present in the leukaemic clone enabled us to assess the state
of biological remission in this patient at an early stage of
posttransplant. Haematological remission in advanced ALL
rarely occurs after chemo-radiotherapy and matched allo-
geneic transplant in relapse. The achievement of “molecular
remission” in this case, at an early stage posttransplant, sug-
gests that if GVHD/GVL had occurred, then the remission
might have been enhanced. Unfortunately, after 8 months
in remission, the leukaemia relapsed, with return of all the
clonal molecular markers. (Patients transplanted in relapse
have the highest likelihood of disease relapse following
transplant, irrespective of the source of stem cells or the
modality of treatment [12]).
Clearly any approach which can lead to quicker and safer
engraftment of cord stem cells in adults where the matched
units are very small is worth furtherexploration and suggests
thatthedoublecordapproachsuccessmaynotjustberelated
to increase of stem cell numbers. It seems possible that our
ﬁndings in this case might tempt the experimentalists with
an animal model to further deﬁne the possible biological
mechanisms operating in multicord transplant.
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